Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mircea Dediu

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Lung Cancer (Amsterdam, Netherlands)|April 17, 2002
Is long term gemcitabine useful in small cell lung cancer?Mircea Dediu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Should we discard vinorelbine plus cisplatin from the first-line therapy of advanced non-small-cell lung cancer?Mircea Dediu
Breast Care (Basel, Switzerland)|August 11, 2020
Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624]Mircea Dediu, Christoph Zielinski
Breast Care (Basel, Switzerland)|April 2, 2020
A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast CancerMircea Dediu, Christoph Zielinski
Memo|April 3, 2018
ESMO 2017-my personal highlightsBarbara Kiesewetter, Mircea Dediu, Rupert Bartsch
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|January 1, 2017
Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in changeMircea Dediu, Florentina Bratu, Mihaela Amarandei, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the LungCatalin Buium, Serban Negru, Diana N Ionescu, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|November 6, 2007
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinibMircea Dediu, Dragos Median, Aurelia Alexandru, et al.
Oncology Research and Treatment|December 4, 2022
Perspectives for Cancer Care and Research in Central and Eastern EuropeChristoph C Zielinski, Tanja Cufer, Bostjan Seruga, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2009
XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapyUlrich Gatzemeier, Tudor Ciuleanu, Mircea Dediu, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Lung Cancer (Amsterdam, Netherlands)|April 17, 2002
Is long term gemcitabine useful in small cell lung cancer?Mircea Dediu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Should we discard vinorelbine plus cisplatin from the first-line therapy of advanced non-small-cell lung cancer?Mircea Dediu
Breast Care (Basel, Switzerland)|August 11, 2020
Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624]Mircea Dediu, Christoph Zielinski
Breast Care (Basel, Switzerland)|April 2, 2020
A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast CancerMircea Dediu, Christoph Zielinski
Memo|April 3, 2018
ESMO 2017-my personal highlightsBarbara Kiesewetter, Mircea Dediu, Rupert Bartsch
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|January 1, 2017
Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in changeMircea Dediu, Florentina Bratu, Mihaela Amarandei, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the LungCatalin Buium, Serban Negru, Diana N Ionescu, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|November 6, 2007
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinibMircea Dediu, Dragos Median, Aurelia Alexandru, et al.
Oncology Research and Treatment|December 4, 2022
Perspectives for Cancer Care and Research in Central and Eastern EuropeChristoph C Zielinski, Tanja Cufer, Bostjan Seruga, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2009
XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapyUlrich Gatzemeier, Tudor Ciuleanu, Mircea Dediu, et al.
Pageof 3